Gene editing to facilitate hybrid crop production.
Apomixis
CRISPR/Cas9
Crop hybrids
Gene editing
Haploids
Heterosis
Male fertility
Journal
Biotechnology advances
ISSN: 1873-1899
Titre abrégé: Biotechnol Adv
Pays: England
ID NLM: 8403708
Informations de publication
Date de publication:
Historique:
received:
22
08
2020
revised:
23
11
2020
accepted:
28
11
2020
pubmed:
8
12
2020
medline:
27
4
2021
entrez:
7
12
2020
Statut:
ppublish
Résumé
Capturing heterosis (hybrid vigor) is a promising way to increase productivity in many crops; hybrid crops often have superior yields, disease resistance, and stress tolerance compared with their parental inbred lines. The full utilization of heterosis faces a number of technical problems related to the specifics of crop reproductive biology, such as difficulties with generating and maintaining male-sterile lines and the low efficiency of natural cross-pollination for some genetic combinations. Innovative technologies, such as development of artificial in vitro systems for hybrid production and apomixis-based systems for maintenance of the resulting heterotic progeny, may substantially facilitate the production of hybrids. Genome editing using specifically targeted nucleases, such as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated nuclease 9 (CRISPR/Cas9) systems, which recognize targets by RNA:DNA complementarity, has recently become an integral part of research and development in life science. In this review, we summarize the progress of genome editing technologies for facilitating the generation of mutant male sterile lines, applications of haploids for hybrid production, and the use of apomixis for the clonal propagation of elite hybrid lines.
Identifiants
pubmed: 33285253
pii: S0734-9750(20)30178-6
doi: 10.1016/j.biotechadv.2020.107676
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
107676Informations de copyright
Copyright © 2020. Published by Elsevier Inc.